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The impact of Bariatric Surgery on 
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Management of Hypoglycemic events
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Recent studies discussed the benefit of bariatric surgery on obese patients diagnosed 
with type 2 diabetes mellitus (T2DM). Several factors play an essential role in predicting 
the impact of bariatric surgery on T2DM, such as ABCD score (age, BMI, C-peptide, 
and duration of the disease), HbA1c, and fasting blood glucose, incretins [glucagon-like 
peptide-1 (GLP-1) and gastric inhibitory peptide (GIP)]. DiaRem score known to include 
factors such as age, HbA1c, medication, and insulin usage used to predict the remission 
of T2DM, but it has some limitations. An extensive literature search was conducted on 
PubMed and Google Scholar using keywords such as gastric bypass, T2DM, bariatric 
surgery, GLP-1, GIP, and post bariatric hypoglycemia. Restrictive-malabsorptive proce-
dures are most effective in treating T2DM patients based on changes induced in appetite 
through regulation of gastrointestinal hormones, with decreased hunger and increased 
satiation. We provide a review of bariatric surgery influence on T2DM and management of 
post-intervention hypoglycemic events. Post-bariatric surgery hypoglycemia is a serious 
complication especially when patients develop life-threatening neuroglycopenia with loss 
of consciousness and seizure. The avoidance of this adverse event may be achieved by 
strict dietary modification including a restriction on carbohydrates as well as foods with 
high glycemic index. Further research will provide more information on post-bariatric 
surgery hyperinsulinemic hypoglycemia pathophysiology and management.
Keywords: bariatric surgery, Roux-en-Y gastric bypass, post-bariatric surgery hypoglycemia, glucagon-like 
peptide-1, type 2 DM, C-peptide
inTRODUCTiOn
Obesity is one of the 10 leading US health indicators of increased risk of pulmonary diseases, car-
diovascular diseases, diabetes, musculoskeletal diseases, and certain forms of cancers. The increasing 
prevalence of obesity in adult population triggered a concomitant rise in type 2 diabetes mellitus 
(T2DM) (1, 2). Obesity and insulin resistance are the main components of metabolic syndrome 
and result in impaired glucose metabolism. Those who suffer from both conditions are recently 
referred to as “diabesity patients” (3). Different obesity treatment strategies have been used, includ-
ing prevention, lifestyle and dietary modification, behavioral therapy, and pharmacotherapy (1). 
A recent article published by Patti and Goldfine concluded that current therapies are not effective in 
providing a sustained weight loss (4). Of the various treatment options, bariatric surgery remains the 
most effective method to achieve a long-term weight loss (5, 6). Post-surgical weight loss improves 
all obesity-related comorbidities with a good quality of life and decreased overall mortality rate 
TaBle 1 | aBCD grading system used to predict the success of bariatric 
surgery on type 2 diabetes mellitus (T2DM) remission.
Factor Score
age (years)
<40 1
≥40 0
BMi (kg/m2)
<27 0
27–34.9 1
35–41.9 2
≥42 3
C-peptide (ng/ml)
<2 0
2–2.9 1
3–3.9 2
≥5 3
Duration of DM (years)
>8 0
4–8 1
1–3.9 2
<1 3
Total score calculated by adding each of the four variables 0–10
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(7–9). Also, post-bariatric surgical patients have demonstrated 
83% reduction in diabetes incidence, 30–40% reduction in 
myocardial infarction and stroke, 42% reduction of cancer in 
women, and 30–40% reduction in overall mortality (4). There are 
several bariatric procedures currently available including lapa-
roscopic adjustable gastric banding (LAGB), laparoscopic sleeve 
gastrectomy (LSG), the biliopancreatic diversion with duodenal 
switch (LBPD-DS), and laparoscopic Roux-en-Y gastric bypass 
(LRYGB) (10).
PubMed and Google Scholar were searched for relevant 
articles. The following keywords and phrases were used in 
various combinations: gastric bypass, sleeve gastrectomy, T2DM, 
laparoscopic bariatric surgery, GLP-1, GIP, and post bariatric 
hypoglycemia. All articles identified within the initial search 
were screened for relevance and content, and their bibliographies 
were searched for any additional relevant articles. The criteria for 
inclusion were articles considering T2DM remission after bariat-
ric surgery and post-bariatric surgery hypoglycemia (PBH). All 
publications up to June 2016 were considered.
BaRiaTRiC PROCeDUReS
Laparoscopic adjustable gastric banding was the first bariatric 
technique to be performed by a laparoscopic approach. The 
operation is done by creation of a small pouch in the upper part 
of the stomach with a controlled and adjustable stoma, without 
stapling, thus limiting food intake. The band is fitted around the 
fundus of the stomach, forming a 15–20  ml small pouch. The 
diabetes remission after LAGB can be achieved gradually and is 
associated with the degree of weight loss (11).
Laparoscopic sleeve gastrectomy is a simple surgical 
technique with a low complication rate and minor long-term 
nutritional deficiencies. The operation is performed by resecting 
the greater curvature from the distal antrum (4 cm proximal to 
the pylorus) to the angle of His, including the complete fundus, 
by using a laparoscopic stapler. The remnant stomach tube was 
approximately 2 cm wide along the less curved side. The resected 
portion of the stomach was extracted from the extended peri-
umbilical trocar site (12). A prospective study done by Silecchia 
et al. included 41 super-obese patients demonstrated that at 18th 
month post SG, diabetes was cured in 76.9% and improved in 
15.4% of patients (13).
LBPD-DS, in this operation, is a 60% distal gastric resection 
with stapled closure of the duodenal stump results in a residual 
stomach volume of ~300 ml. The small bowel is transected 2.5 m 
from the ileocecal valve, and its distal end is anastomosed to the 
remaining stomach. The proximal end of the ileum, comprising 
the remaining small bowel carrying the biliopancreatic juice 
and excluded from food transit, is anastomosed to the bowel 
50 cm proximal to the ileocecal valve. Consequently, the total 
length of absorbing bowel is 250 cm, the final 50 cm of which 
represents the site where ingested food and biliopancreatic 
juices mix (14).
Laparoscopic Roux-en-Y gastric bypass surgery, a restrictive 
and malabsorptive technique, is performed frequently in Canada 
and the US (112,000 procedures annually) (15, 16). In Europe, 
this technique is increasingly popular, with more than 26,000 
procedures performed annually (16). A gastric pouch is created 
by completely separating stomach from the gastric remnant and 
anastomosed to the jejunum. An entero–entero anastomosis is 
created between the alimentary limb and pancreatobiliary limb, 
75–150  cm distally from the gastrojejunostomy. The intake of 
food is restricted by gastric pouch and nutrients absorption is 
reduced by bypassing the duodenum and part of the jejunum 
(17). A recent study published in 2015 done by Yska et al. examin-
ing T2DM remission rate in patients who underwent bariatric 
surgery compared with T2DM patients without surgery demon-
strated that LAGB had a smaller effect on T2DM remission than 
LRYGB and LSG (18).
PReOPeRaTive PReDiCTive FaCTORS 
OF T2DM ReMiSSiOn
Numerous studies have established the effect of bariatric surgery 
on remission or improvement of T2DM can be predicted by 
considering a number of factors (14, 19). A prospective cohort 
study published in 2014 by Itariu et al. concluded that the ABCD 
score (age, BMI, C-peptide, duration of the disease, also called 
the diabetes surgery score) is a simple multifactorial grading 
system that can predict the success of bariatric surgery on T2DM 
remission (see Table 1). The score contains four hubs, the degree 
of obesity (BMI), islet cell mass (C-peptide level), competence 
of B-cell function (T2DM duration), and the general leverage of 
body function (patient age) (20). The benefit of bariatric surgery 
in diabetic patients with BMI < 27 kg/m2 is reduced, and the pro-
cedure is not recommended for diabetes treatment (21, 22). Since 
chronic T2DM damages a large percentage of B-cells, patients with 
a short history of the disease are known to experience a greater 
benefit from surgery compared to those with a longer history 
of illness (22). C-peptide level is considered a mirror of insulin 
secretion, indicating the percentage of insulin secretion, B-cell 
TaBle 2 | DiaRem grading system used to predict the success of 
bariatric surgery on type 2 diabetes mellitus (T2DM) remission.
Factor Score
age (years)
<40 0
40–49 1
50–59 2
≥60 3
Hba1c (%)
<6.5 0
6.5–6.9 2
7–8.9 4
≥9.0 6
Other diabetes drugs
No sulfonylureas or insulin-sensitizing agents other than metformin 0
Sulfonylureas and insulin-sensitizing agents other than metformin 3
Treatment with insulin
No 0
Yes 10
Total score calculated by adding each of the four variables 0–22
3
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functions, and surgical effect on T2DM remission (23). Patient 
age, per se, is considered to be of little value, but may predict the 
general physiological outcome, advanced age patients reporting 
minor benefits from undergoing bariatric surgery (24). Lee et al. 
compares the ABCD score (Table 1) with DiaRem score (Table 2) 
known to include factors as age, HbA1c, medication, and insulin 
usage. They suggested that the ABCD score is superior to DiaRem 
score, due to the limitations encountered by the latter. DiaRem 
score does not reflect the duration of T2DM (an example of the 
limitations), which is often considered the crucial predicting fac-
tor of diabetes remission.
Furthermore, DiaRem score was developed based on studies 
enrolling patients with a mean BMI of 48.8  kg/m2 undergoing 
bariatric surgery regardless diabetes status (25).
MeCHaniSMS OF T2DM ReMiSSiOn 
aFTeR BaRiaTRiC SURGeRY
Several studies suggested that a decrease in plasma glucose level 
in T2DM patients after bariatric surgery is a result of a caloric 
restriction, not of a significant weight loss. Even though any 
decrease in caloric intake can improve plasma glucose levels and 
liver fat content, the mechanism of T2DM remission after bari-
atric surgery is still not fully elucidated (26). Numerous studies 
postulated that intestinal hormonal changes after bariatric surgery 
play an important role in T2DM remission and developed two 
hypotheses: the hindgut hypothesis and the foregut hypothesis. 
The hindgut hypothesis of T2DM remission proposes that fol-
lowing bypass surgery, there is a rapid delivery of nutrients to the 
distal intestine stimulating L-cell secretion of anorexigenic and 
antidiabetic peptides, including GLP-1 and peptide YY (27, 28). 
This hypothesis focuses on GLP-1 because its effects on B-cells 
proliferation and insulin production (29). The foregut hypothesis 
states that bypassing the proximal small intestine the secretion of 
anti-incretin hormones is diminished and blood glucose control 
is improved (28). Gastric inhibitory peptide (GIP) is another 
incretin responsible for increased postprandial insulin release 
after bypass surgery (30).
Ghrelin is a 28-amino acid polypeptide hormone produced 
mainly by endocrine A-like cells in the gastric and duodenum 
epithelia being responsible for appetite stimulation; its concentra-
tion is reduced after bypass surgery as a result of lack of food 
stimulus (31).
Changes are also seen in adipocyte-derived hormones, leptin is 
correlated with insulin resistance whereas adiponectin enhances 
insulin sensitivity (32). After bypass surgery, a decrease in leptin 
level and a rise in adiponectin concentration are noted (33, 34). A 
recently published study investigating adipocyte-derived exoso-
mal microRNAs after gastric bypass showed that there are major 
changes in these microRNAs which correlated to improvement 
of insulin resistance and metabolomic changes consistent with 
improved glucose homeostasis (35).
A randomized controlled trial comparing RYGB to a lifestyle 
intervention included Taiwanese and American patients pub-
lished in 2016 by Chong et al. found that RYGB was associated 
with better improvement and remission of diabetes in both 
ethnicities (36).
As the aforementioned findings indicate, success of T2DM via 
bariatric surgery can be predicted and that the actual mechanism 
supporting these phenomena appears multifactorial and may 
involve changes in gut- and adipocyte-derived hormones (37).
PBH anD iTS ManaGeMenT
One of the severe complications of Roux-en-Y gastric bypass 
surgery is PBH, first described by Service et al. in 2005 and sub-
sequently confirmed by other authors (38–40). PBH is defined 
as a delayed onset hypoglycemia (1–2  h after a meal) without 
vasomotor symptoms. This presentation differs from early 
dumping syndrome characterized by fast onset (10–30 min after 
food intake) due to rapid food entrance into the intestine, and 
accompanied by an increased osmotic effect, with a fall in blood 
pressure and rise in heart rate (41).
Hypoglycemic symptoms can be classified as autonomic 
(such as palpitations, lightheadedness, sweating, anxiety, trem-
ors, hunger) or neuroglycopenic (such as fainting, dizziness, 
blurred vision, weakness, confusion, decreased attentiveness, 
seizure, loss of consciousness). Autonomic symptoms occur 
when the glucose level drops below 3.3 mmol/l (60 mg/dl), and 
neuroglycopenic symptoms predominate when the level drops 
below 2.8  mmol/l (50  mg/dl) (42). Hypoglycemic symptoms 
experienced early in the postoperative period are often associ-
ated with dumping syndrome and are effectively treated with 
low glycemic index diets. More severe hypoglycemia associated 
with neuroglycopenia is manifested as a loss of consciousness, 
seizure activities, and typically reported 1–3 years after gastric 
bypass (4). To confirm that symptoms are related to hypoglyce-
mia, venous blood sampling should demonstrate glucose values 
<70  mg/dl (3.9  mmol/l), and fast improvement of symptoms 
after glucose ingestion. Also, plasma insulin concentrations are 
inappropriately high at the time of hypoglycemia, indicating 
dysregulation of insulin secretion as an important mechanism 
(4). The published prevalence of hypoglycemia following 
4Kassem et al. Bariatric Surgery and Diabetes Mellitus
Frontiers in Endocrinology | www.frontiersin.org March 2017 | Volume 8 | Article 37
bariatric surgery varies, depending on the applied definition, 
with a range of 0.2% for patients requiring hospitalization for 
severe hypoglycemia to 72% for reactive hypoglycemia after 
a glucose tolerance test (43, 44). A better understanding of 
hypoglycemia mechanism in post-bariatric surgery patients will 
improve the glycemic control management (39, 45). A common 
hypothesis for PBH supports the evidence that increased secre-
tion and action of GLP-1 enhances the cell response to meal 
ingestion, entertaining hypoglycemic events (40). GB recipients 
present higher plasma levels of GLP-1 and greater GLP-1 action 
to increase insulin release than individuals who did not require 
this intervention. According to studies testing GLP-1 receptor 
antagonists (exendin-9) during meal ingestion, no difference 
was reported on postprandial GLP-1 receptor antagonist 
action on hypoglycemic versus normoglycemic individuals 
(46). Service et al. proposed a possible mechanism responsible 
for the development of PBH due to islet cell hyperplasia with 
amplification of beta cell mass that contribute to increased 
insulin level and subsequent hypoglycemia (39). Other poten-
tial mechanisms have been suggested such as altered intestinal 
microbiota, augmented bile acids, and enhanced glucose efficacy 
(4, 47). Thus, the mechanisms of postprandial hypoglycemia in 
GB subjects are complex remain unknown (40). Therapeutic 
approaches to prevent hypoglycemia following RYGB are not 
standardized. Medical treatment is directed toward maintaining 
blood glucose levels within normal limits (48). PBH patients 
usually develop a postprandial high glucose level following 
carbohydrate-enriched food consumption stimulates GLP-1 and 
insulin release, with a rapid drop of glucose level and subsequent 
hypoglycemia. A carbohydrate restrictive diet “high glycemic 
index food and simple sugars” address symptoms and prevents 
hypoglycemia and hyperinsulinism (49–51). Other dietary 
interventions such as increased dietary fiber intake and avoiding 
alcohol consumption are responsible for a decrease in glucose 
absorption and improved postprandial hypoglycemia (52–55). 
Bantle et  al. and Tappy and Mittendorfer demonstrated that 
fructose can be ingested safely by PBH patients, with avoidance 
of over consumption and undesirable effect on metabolic health 
(56, 57). McLaughlin et al. suggested that post RYGB patients 
with neuroglycopenic symptoms improved after gastrostomy 
and continuous enteral feeding with decreased glucose and 
insulin levels and significantly lower values of GLP-1, GIP, and 
glucagon when compared with previous oral nutrition (58). 
Medications, such as acarbose, diazoxide, octreotide, or vera-
pamil have been known to successfully treat this unexpected 
surgical outcome (1, 59). Acarbose is effective in reducing blood 
sugar level, plasma insulin levels, and GLP-1 (60). Common 
side effects associated with acarbose were bloating, flatulence, 
or diarrhea (10). Combination of verapamil with acarbose was 
found to be effective in PBH (61). Hypotension and edema 
are common side effects associated with verapamil use (10). 
Diazoxide inhibits insulin release through the activation of 
ATP-sensitive potassium channel (62). Diazoxide use may be 
responsible for hypotension, fluid retention, and hirsutism 
(10). Octreotide is advised when diet, α-glucosidase, and 
calcium channel blockers have not been effective (63). Invasive 
procedures, for instance restoring gastric restriction with an 
adjustable gastric band, placing gastrostomy tube, subtotal, or 
total pancreatectomy, are considered as a part of the treatment 
(1, 58, 59, 64). However, preoperative individual risk assessment 
is required as long as factors predicting PBH following bariatric 
surgery are still investigated (61).
COnClUSiOn
Diabetes remission, improvement of blood glucose control, and 
reduction of antidiabetic medications after bariatric surgery can 
be sustained for many years with a decrease in overall morbidity 
and mortality. There are grading systems to predict T2DM remis-
sion success and that while the mechanisms supporting this are 
not fully understood there are a number of hormonal changes 
that may play a significant role in stabilizing blood glucose levels, 
improving insulin sensitivity, and regulating appetite which over-
all have a beneficial effect on T2DM. Restrictive-malabsorptive 
procedures are known to improve glucose homeostasis, insulin 
sensitivity, and B-cells secretory function. Bariatric surgery can 
be considered as a second-line therapy in non-obese diabetic 
patients. In non-diabetic morbidly obese patients, bariatric surgery 
may prevent the development of T2DM and other comorbidities. 
PBH is a serious complication, dysregulation of insulin secretion 
with hyperinsulinemic state being the most important predicting 
factor for this group of surgical patients. Food restriction is the 
first-line therapy for this condition and if failed, pharmacologi-
cal management should be considered. Pancreatectomy may be 
required for limited cases. Further research should identify the 
patient population at risk for post-bariatric hypoglycemia and 
elaborate on the effective treatment. The metabolic benefits, as 
well as short- and long-term surgical complications, should be 
considered when the patient is advised to proceed with surgery.
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